Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762150 | 0.90 | NAMPT (0.62) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6283335 | 0.87 | NAMPT (0.64) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL12010884 | 0.86 | NAMPT (0.72) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL7536021 | 0.85 | CCR3 (0.54) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2762018 | 0.82 | MEN1 (0.54) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL23059729 | 0.82 | NAMPT (0.63) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL20380297 | 0.81 | NAMPT (1.00) | NAMPT | |
| SCHEMBL2762003 | 0.81 | MAPT (0.68) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2762125 | 0.80 | CA2 (0.60) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6282309 | 0.80 | MAPT (0.60) | NAMPTMEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-2391601-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086177-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
| US-6949567-B2 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1395548-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2002070467-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | NAMPT 1150/4885MEN1 2642/4885MAPT 2767/4885 |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | CLIC1, PKD2, PKD1 | NAMPT 4286/4885MEN1 1654/4885MAPT 2803/4885 |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | SLC14A1, UTS2R, UROD | NAMPT 404/4885MEN1 2878/4885MAPT 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.